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Attention deficit hyperactivity disorder (ADHD) is thought to be associated with
dysfunction of ascending catecholamine neuronal systems, particularly dopamine (DA) and
norepinephrine (NE). Dysfunction of these catecholamine neurons innervating the prefrontal
cortex is hypothesized to underlie impaired executive functions. Dysfunction of the DA neurons
innervating the striatum is additionally hypothesized to underlie deficits in motivation and
reinforcement learning. However, mechanisms of action of therapeutic drugs used for treating
ADHD have mainly focused on catecholamines in the prefrontal cortex and have not adequately
addressed the role played by DA signaling in the striatum. Stimulants such as Adderall® and
Ritalin® are chemically considered “amphetamines”. While effective for treating ADHD, there
are grave concerns about stimulant abuse with this drug class. The more recently developed
Strattera®, a non-stimulant used to treat AHDH, offers a non-addictive alterative. However, how
Strattera® acts pharmacologically in the brain is not completely established. Our study
investigates the brain mechanisms of Strattera® and specifically examines how Strattera® acts on
brain dopamine neurons, which are important for learning. The second part of the study
investigates the mechanism of action of the stimulant class of drugs. Stimulants act on brain
dopamine neurons by blocking a protein that removes dopamine after its release to terminal
neurotransmission. This action is thought to underlie the addictive potential of stimulants. We are

pursuing a novel action of stimulants: increasing the dopamine released by action potential
dependent exocytosis. This action would increase brain dopamine, thereby mediating some of the
pharmacological effects of stimulants. Collectively, our studies provide insight into how important
drugs used clinically and often are abused act on the brain. The long-term goal is to distinguish
the clinically efficacious component of these drugs from their addictive potential, which should
help drive development of safer drugs for treating ADHD.
KEYWORDS: Dopamine; Atomoxetine; Psychostimulants; Amphetamine; Modafinil; Cocaine;
Phasic dopamine signaling; Transients; DAT-inhibitor.

DOPAMINE EFFECTS OF STIMULANT AND NON-STIMULANT DRUGS USED IN THE
TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

PREETI CHALWADI

A Dissertation Submitted in Partial
Fulfillment of the Requirements
for the Degree of
DOCTOR OF PHILOSOPHY
School of Biological Sciences
ILLINOIS STATE UNIVERSITY
2017

© 2017 Preeti Chalwadi

DOPAMINE EFFECTS OF STIMULANT AND NON-STIMULANT DRUGS USED IN THE
TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER

PREETI CHALWADI

COMMITTEE MEMBERS:
Paul A. Garris, Chair
Craig Gatto
Wolfgang Stein
Joe Casto
Byron Heidenreich

ACKNOWLEDGMENTS
I would like to express my heartfelt gratitude towards my advisor, Dr. Paul Garris, for
being an excellent mentor. I thank him for his immense patience and constant encouragement
throughout the course of my PhD studies. His intellectual brilliance is matched only by his
genuinely good nature and his humility. I could not have asked for a better advisor.
I would also like to thank my committee members, Drs. Craig Gatto, Wolfgang Stein, Joe
Casto, and Byron Heidenreich, for their insightful questions and comments for my research work,
and for the general collegiality each of them offered to me over the years. My sincere thanks to
Dr. Craig Gatto, who as department chair, helped me move through various obstacles during my
PhD with much ease.
I thank all members of the Garris lab present during my graduate career, who proved an
invaluable resource for my growth as a graduate student. In particular, I am grateful to Doug
Schuweiler, Martin Bobak, Matthew Weber, and Melissa Doellman, who taught me the
experimental procedures necessary to carry out the research.
I also wish to express my thanks to Mrs. Khushie Curmally, for leaving no stone unturned
in her efforts to ensure that I meet my educational goals in the USA without feeling burdened. I
am overwhelmed by her compassion and generosity. I would be remiss not to mention the
invaluable support of my friends Niket Bhodia, Aditi Vyas, and Suranjana Sen, who have stood
by me through thick and thin over the years, showing great love and graciousness. In a similar
vein, I would like to acknowledge Sarita Sharma, Aditya Airen, Dheeraj Reddy, Saket Jangle,
Akanksha Shukla, and Aditya Bennuri for their kindness and for helping me tide through some
challenging times.
I owe my success, in a large way, to my family. Most importantly, I am grateful to my
mother, Anu Chalwadi, for her innumerable sacrifices in bringing me up to be where I am today.
Her love has been my biggest strength as I pursued this final degree. My grandparents, Mr.
Hanumanta Chalwadi and Mrs. Gangamma Chalwadi, have always been with me in spirit
throughout my dissertation and my life in general. I am also tremendously thankful to my uncles
Nityanand Chalwadi, Sukmani Chalwadi, Mallesh Chalwadi, and Gangadhar Penta whose support
and protection have been a blessing for me.
P.C.

i

CONTENTS
Page
ACKNOWLEDGMENTS

i

CONTENTS

ii

CHAPTER I FIGURES

v

CHAPTER II FIGURES

vi

CHAPTER II SUPPLEMENTARY FIGURES

vi

CHAPTER I: EFFECT OF ATOMOXETINE ON PHASIC DOPAMINE SIGNALING

1

Abstract

1

Introduction

2

Materials and Methods

5

Animals

5

Surgery

5

Experimental design

6

Electrochemistry

7

Electrical stimulation

7

Data analysis

8

Statistics

8

Drugs and chemicals

9

Results

9

I.p. drug administration

9

ATX does not alter electrically evoked phasic-like DA signals

10

ATX activates DA transients

11

ATX and basal DA

12
ii

Discussion

13

ATX and electrically evoked phasic-like DA signals

14

ATX and basal DA levels

15

ATX activates DA transients in the ventral striatum

16

Therapeutic action of ATX in ADHD

17

Conclusion

18

References

19

Chapter I Figures

28

CHAPTER II: DOPAMINE TRANSPORTER-INHIBITING PSYCHOSTIMULANTS
INCREASE EXOCYTOTIC DOPAMINE RELEASE

34

Abstract

34

Introduction

35

Results and Discussion

38

Correction of raw FSCV signals

38

Restricted diffusion model with hang-up correction produces better fits

40

MOD alters DA release and uptake in the dorsal striatum of anesthetized rats

40

Fitting of PCR-treated data

42

AMPH alters DA release and uptake in the dorsal striatum of freely behaving
rats

43

AMPH and cocaine alter DA release and uptake in the dorsal striatum of
anesthetized rats

45

Methods

46

Data

46

Animals

47

Surgery

47

iii

FSCV

48

Data Analysis

48

Diffusion gap model

48

Restricted diffusion model

49

Hang up correction

50

pH correction

50

PCR

51

Statistics

51

Drugs and chemicals

51

Conclusion

52

References

56

Chapter II Figures

63

Chapter II Supplementary Figures

72

iv

CHAPTER I FIGURES
Figure

Page

1. Experimental design and data analysis

30

2. Effects of ATX, RAC, and AMPH (i.p) on electrically evoked phasic-like DA signals

32

3. Effects of SAL, ATX, RAC, and AMPH on electrically evoked phasic-like DA signals

33

4. Effects of SAL, ATX, RAC, and AMPH on DA transients

34

5. Effects of ATX, RAC, and AMPH on changes in basal DA in the ventral striatum

35

v

CHAPTER II FIGURES
Figure

Page

1. Schematic representation of DG and RD models

66

2. Hang-up correction of electrically evoked DA signals

67

3. pH correction of electrically evoked DA signals

68

4. Hang-up correction of PCR-resolved DA signals

69

5. Comparison of fits obtained by DG and RD models

70

6. Modafinil activates exocytotic DA release and reduces DA uptake

71

7. Modafinil increases DA release and reduces DA uptake in PCR-treated DA traces

72

8. Amphetamine activates exocytotic DA release and reduces DA uptake

73

9. Comparison of effects of AMPH and cocaine on DA release and uptake

74

vi

CHAPTER II SUPPLEMENTARY FIGURES
Figure

Page

S1. Two-way repeated measures ANOVA of DA signals altered by MOD (300 mg/kg) and
collected in anesthetized rats

75

S2. Two-way repeated measures ANOVA of DA signals altered by AMPH (10 mg/kg) and
collected in awake rats

76

S3. Two-way repeated measures ANOVA of DA signals altered by AMPH (10 mg/kg) and
cocaine (40 mg/kg) and collected in anesthetized rats

77

vii

CHAPTER I
EFFECT OF ATOMOXETINE ON PHASIC DOPAMINE SIGNALING
Abstract
Attention deficit hyperactivity disorder (ADHD) is thought to be associated with
dysfunction of ascending catecholamine systems in the brain, particularly dopamine (DA) and
norepinephrine (NE). Dysfunction of these catecholamine neurons innervating the prefrontal
cortex is hypothesized to underlie impaired executive functions. Dysfunction of the DA neurons
innervating the striatum is additionally hypothesized to underlie deficits in motivation and
reinforcement learning. However, investigating mechanisms of action of therapeutic drugs used
for treating ADHD has mainly focused on catecholamines in the prefrontal cortex and have not
adequately addressed the role played by DA signaling in the striatum. The present study addresses
this issue by examining the neuropharmacologic mechanism of atomoxetine (ATX), a potent and
selective NE reuptake inhibitor, on phasic DA signaling in the striatum of anesthetized rats. ATX,
a non-stimulant approved for ADHD treatment in the form of Strattera®, is suggested to produce
its therapeutic effects by enhancing catecholamine transmission in the prefrontal cortex. We
propose that in addition to its remedial effects in the prefrontal cortex, ATX enhances phasic DA
signaling in the striatum. We found ATX to activate DA transients, the extracellular component
of phasic DA signaling occurring in DA terminal fields and elicited by burst firing of DA neurons,
which were measured by fast-scan cyclic voltammetry at a carbon-fiber microelectrode. This study
is neurobiologically significant, because it leads to a better understanding of the role NE plays in
regulating phasic DA signaling in the striatum. Moreover, this study sheds light on the
incompletely understood therapeutic mechanism of action of ATX and hence, may contribute
towards development of better drugs for treating ADHD.
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Introduction
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with an
onset in childhood and can continue into adolescence and adulthood. 5% of the children in the
United States have ADHD (American Psychiatric Association, 2013). According to the DSM-5,
ADHD is characterized by insufficient levels of attention and high levels of impulsivity and
hyperactivity. These symptoms have been linked to deficits in executive function, response
inhibition, and reinforcement learning, which in turn result from an underlying brain dysfunction,
particularly the prefrontal cortex (PFC) and the striatum. While the PFC is involved in executive
functions, such as inhibition of inappropriate behavior, planning, organization, and attention
(Arnsten & Li, 2005), the striatum is important in processing reward-related information (Apicella
et al., 1991; Kawagoe et al., 1998). Various imaging studies have pointed towards hypo-functional
PFC (Castellanos et al., 1996) and striatal activity as pivotal pathophysiologic features of ADHD
(Aston-Jones et al., 2000; Lou et al., 1989). The catecholamines, specifically dopamine (DA) and
norepinephrine (NE), and their dysfunctional modulation of the prefrontal and striatal circuits are
the principal neuropharmacologic target in treating ADHD (Castellanos & Tannock, 2002).
Models of ADHD pathophysiology include the inverted-U model, which describes PFC
function and dysfunction using an inverted-U dose-response curve for both DA and NE (Levy,
2009). It hypothesizes that in individuals with ADHD, catecholamines are present at lower than
optimal levels. Low catecholamine levels result in an underactive PFC, due to diminished
activation of the D1 and α-2 adrenergic receptors by DA and NE, respectively (Aston-Jones et al.,
2000; Arnsten & Pliszka, 2011). Another model, called the dopamine transfer deficit (DTD)
model, addresses the role of the striatum in ADHD. The DTD model describes a neuronal
mechanism whereby ADHD patients show altered reinforcement learning, during which the
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reward (reinforcer) becomes associated with a predictive cue over time (Berridge, 2001). Early in
reinforcement learning, the DA transient, an extracellular phasic signal initially elicited by the
reward activating burst firing of DA neurons (Schultz, 1998), is transferred in part, to the
predictive stimulus, but it also remains activated by the reward itself. Later in learning, the DA
transient is solely elicited by the predictive cue (Tripp & Wickens, 2008). The DTD model
proposes that in individuals with ADHD, this transfer of the DA transient from the reward to the
cue is disturbed, such that the cue-evoked DA transient is weak, leading to ineffective
reinforcement learning (Tripp & Wickens, 2008).
Medications approved by the Food and Drug Administration for treating ADHD include
psychostimulants, such as amphetamine (AMPH; Adderall) and methylphenidate (MPH; Ritalin),
and more recently, a non-stimulant, atomoxetine (ATX; Strattera®) (Bymaster et al., 2002). All
of these ADHD drugs increase extracellular NE and DA concentrations in the brain by blocking
their uptake; specifically, AMPH and MPH block the NE transporter (NET) and the DA
transporter (DAT), whereas ATX selectively inhibits NET. In terms of therapeutic implications
of the inverted-U model, it is suggested that ADHD drugs elevate extracellular levels of DA and
NE in the PFC and hence, improve PFC functionality (Arnsten, 2006). Microdialysis studies show
that ATX, AMPH, and MPH increase NE and DA levels in the PFC (Bymaster et al., 2002;
Berridge & Stalnaker, 2002; Berridge & Stalnaker, 2002; Berridge & Stalnaker, 2002). While
AMPH and MPH also increase extracellular DA in the striatum (Kuczenski & Segal, 2001;
Berridge et al., 2006), ATX does not (Bymaster et al., 2002). Taken together, these results suggest
that ADHD drugs elicit these catecholamine effects preferentially, and in the case of ATX,
exclusively, in the PFC. However, microdialysis has limited temporal resolution, preventing the
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assessment of the effects of these drugs on DA transients (Borland et al., 2005; Robinson et al.,
2003), whose dysfunction is implicated in the DTD model of ADHD.
Work in anesthetized rats suggests that ADHD drugs also activate burst firing of DA
neurons. For example, in vivo electrophysiological recordings have shown AMPH and MPH to
elicit burst firing of VTA DA neurons (Shi et al., 2004). AMPH-induced burst firing of DA
neurons was blocked following administration of the α1 NE antagonist, prazosin (Shi et al., 2000;
Shi et al., 2004). Furthermore, AMPH administration failed to produce burst firing of DA neurons
following a forebrain hemisection, severing neuronal projections from the PFC to the midbrain
(Shi et al., 2004). Taken together, these results suggest that NE is an important mediator of the
DA effects of psychostimulants and that PFC afferents to the VTA contribute to eliciting burst
firing of the DA neurons. High-affinity NET inhibitors such as nisoxetine and reboxetine, which
increase PFC NE levels, also activate DA neuron burst firing (Shi et al., 2000; Linner et al., 2001).
Thus, ADHD medications may elicit their therapeutic effects, at least in part, through activation
of DA neuron burst firing facilitated by increased NE levels and α-1 receptor activation in the
PFC. This activation of DA cell burst firing should in turn give rise to DA transients in the ventral
striatum, a hypothesis not tested to date.
Previous work in our lab using fast-scan cyclic voltammetry (FSCV) at a carbon-fiber
microelectrode (CFM), which exhibits the requisite temporal and chemical resolution to monitor
DA transients with high fidelity (Roberts et al., 2013), has shown AMPH to elicit DA transients
in the striatum (Daberkow et al., 2013; Ramsson et al., 2011; Covey et al., 2013). Whether ATX
also elicits DA transients in this brain region is not known. Psychostimulant ADHD drugs, such
as AMPH, also have presynaptic effects at DA terminals. Not only do they decrease DA uptake,
in keeping with their well-recognized role as DAT inhibitors, but recent evidence suggests that
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they also increase exocytotic DA release (Covey et al., 2013; Daberkow et al., 2013). In the present
study, we thus wanted to investigate whether ATX similarly alters presynaptic DA mechanisms
and DA transients in the striatum. Here we use FSCV at a CFM to monitor electrically evoked
phasic-like DA signals and DA transients. We also used this analytical technique coupled to a
chemometrics approach to monitor changes in basal DA levels in the striatum in order to compare
with previous microdialysis measurements characterizing ATX action. We found that ATX
activates DA transients in the ventral striatum without altering presynaptic DA mechanisms, as
reflected by electrically evoked phasic-liked DA signals and basal DA levels. Taken together, our
results suggest that in addition to increasing PFC levels of DA and NE, ATX activates phasic DA
signaling in the striatum, which could be a novel mechanism mediating its therapeutic efficacy in
treating ADHD.
Materials and Methods
Animals
Adult Sprague-Dawley rats (350-500g) were purchased from Harlan (Indianapolis, IN,
USA) and housed in a light- and temperature-controlled vivarium. Access to food and water was
provided ad libitum. All procedures were in accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by the Institutional
Animal Care and Use Committee of Illinois State University.
Surgery
Adult male Sprague-Dawley rats were anesthetized with urethane (1.6 g/kg, i.p.) and
mounted in a stereotaxic apparatus. An incision of the scalp was made, and skin and fascia
removed. Holes for reference, stimulating, and recording electrodes were drilled through the skull.
All coordinates, anteroposterior (AP), mediolateral (ML) and dorsoventral (DV), are given in mm
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and are referenced to bregma (Paxinos & Watson, 2007). The stimulating electrode was placed in
the medial forebrain bundle (MFB; -4.6 AP, +1.3 ML, -7.5 DV), a CFM targeted the ipsilateral
ventral striatum (+1.2 AP, +1.5 ML, -6.5 DV), and the Ag/AgCl reference electrode was placed
superficially in the contralateral cortex. Final positions of the CFM and stimulating electrode were
based on optimizing the electrically evoked DA signal and were fixed for the duration of the
experiment.
Experimental design
As shown in Figure 1, two experimental designs were used in the present study. In both
designs, DA signals were recorded in 5-min epochs and when applied, electrical stimulation
occurred 5 s into the epoch. Design 1 was used for a pilot set of experiments with drugs
administered i.p. (Fig. 1A). In Design 1a, three pre-drug epochs were followed by twelve ATX
(10 mg/kg), twelve RAC (0.2 mg/kg), and thirteen AMPH (10 mg/kg; administered along with a
second dose of RAC (0.2 mg/kg); positive control) epochs. The order of RAC and ATX
administration was reversed for Design 1b. Electrical stimulation was applied into each pre-drug
epoch, and 30- and 60-min post-drug epochs. These epochs were analyzed for electrically evoked
phasic-like DA signals and DA transients. Figure 1B shows Design 2, which was used for the
remainder of the experiments with drugs administered i.v. In Design 2a, three pre-drug epochs
were followed by two saline (SAL, negative control), two ATX (10 mg/kg), two raclopride (RAC,
0.1 mg/kg), and three AMPH (1 mg/kg; positive control) epochs. The order of RAC and ATX
administration was reversed for Design 2b. Electrically evoked phasic-like DA signals, DA
transients, and changes in basal DA levels were evaluated for each epoch.
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Electrochemistry
DA was recorded using FSCV at a CFM (Roberts et al., 2013). A triangular waveform (0.4 to 1.3 V and back, 400 V/s) was applied to the CFM every 100 ms. CFMs were prepared by
aspirating a single carbon fiber (r = 2.5 μm) into a borosilicate capillary tube (1.2 mm o.d.; Sutter
Instruments, Novato, CA, USA) and pulling to a taper using a micropipette puller (Narishige,
Tokyo, Japan). The carbon fiber was then cut to ~100 µm distal to the glass seal. A Universal
Electrochemistry Instrument (Department of Chemistry Electronic Shop, University of North
Carolina, Chapel Hill, NC, USA) and commercially available software (ESA, Chelmsford, MA,
USA) were used to perform FSCV. CFMs were calibrated in a modified TRIS buffer (Kume-Kick
& Rice, 1998; Wu et al., 2001) after each experiment to convert the current recorded at the peak
oxidative potential for DA (~+0.6 V) to concentration (Wightman et al., 2007). DA was initially
identified by the background subtracted voltammogram (Michael et al., 1998; Heien et al., 2004).
In experiments assessing effects of MOD on basal DA and DA transients, DA was additionally
identified using principal component regression (PCR; see below).
Electrical stimulation
Biphasic stimulation pulses (2 ms each phase) were applied to a twisted bipolar stimulating
electrode (Plastics One, Roanoke, VA, USA), with tips spaced ~1 mm apart. Stimulus pulses were
optically isolated and constant current (Neurolog NL800; Digitimer Limited, Letchworth Garden
City, UK), and delivered as 60-Hz, 24-pulse trains with a current intensity of ±300 µA.
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Data analysis
Figures 1C and D conceptually describe data analyses. To quantify changes in basal DA
(Δ[DA]) and DA transients, the FSCV record was first processed by PCR to resolve DA from the
interferents, pH and background drift (Howard et al., 2013; Covey et al., 2016). PCR-resolved
epochs were accepted if any current not accounted for by the retained principal components of the
training sets, or residual (Q), was less than the 95% confidence threshold (Qα). Δ[DA] was
calculated by averaging all data in the PCR-resolved DA trace of each 5-min epoch after the
baseline has stabilized following electrical stimulation and noise artifacts generated by drug
injection (Fig. 1C, right and left panels). DA transients in the PCR record were identified as peaks
in the non-electrically evoked record greater than 5-times the root-mean-square noise, using peakfinding software (Mini-Analysis, Synaptosoft, Decatur, GA) (Fig. 1C, INSET). The maximal
amplitude of electrically evoked phasic-like DA signals ([DA]max) was analyzed to quantify drug
effects on presynaptic DA mechanisms (Fig. 1D). [DA]max was determined from the raw FSCV,
because at short times DA is the predominant analyte monitored by FSCV with MFB stimulation
(see Fig. 1C).
Statistics
When appropriate, data are presented as the mean ± SEM. One-way repeated-measures
ANOVA, with time or drug as the factor and repeated measures, was used to assess drug effects
on [DA]max, DA transients, and Δ[DA]. Post-hoc comparisons employed the Sidak test. All
statistical analyses were performed using SAS, and significance was set at p < 0.05.
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Drugs and chemicals
Atomoxetine hydrochloride was kindly provided by the Lilly Research Laboratories,
Indianapolis, IN. Raclopride and D-amphetamine were purchased from Sigma (St. Louis, MO,
USA).
Results
I.p. drug administration
Pilot experiments assessing i.p. drug administration were performed using Design 1 shown
in Figure 1A. The order of drug administration in Design 1a (n = 2) was ATX, RAC, and AMPH.
The order of ATX and RAC was reversed in Design 1b (n = 2). Figure 2A shows representative
FSCV recordings demonstrating the effects of ATX, RAC, and AMPH on electrically evoked
phasic-like DA signals measured in the ventral striatum. These evoked DA responses recorded
under pre-drug conditions are considered phasic-like, because they emulate the amplitude and
dynamics of naturally occurring DA transients (Robinson et al., 2008). The individual
voltammogram (INSET in each panel) and pseudo-color plot displaying all voltammograms
collected during the measurement in time (below each [DA] versus time recording) indicate that
DA was the predominate analyte evoked by MFB stimulation for pre-drug and drug conditions.
Compared to the pre-drug recording, RAC increased the maximal amplitude of the electrically
evoked DA signal ([DA]max) and its duration. While ATX did not alter [DA]max or the dynamics
of this signal, AMPH further enhanced its [DA]max and duration.
Drug effects on [DA]max were analyzed by combining the time series of [DA]max (i.e.,
repeating 5-min epochs) into drug groups, as shown in Figure 2B. One-way repeated measures
ANOVA with pseudo-replication was performed and revealed significant effects of drug on
[DA]max for Design 1a (F3,3 = 56.53, p = 0.0039). Post-hoc tests revealed no significant increase
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in [DA]max with ATX (p = 1.0), whereas both RAC (p = 0.047) and AMPH (p < 0.0001)
significantly increased [DA]max compared to pre-drug control. Consistent with representative
recordings, Design 2 showed a significant effect of drug (F3,3 = 81.55, p = 0.0023), and post-hoc
tests showed that RAC significantly increased [DA]max (p < 0.0001), but ATX and AMPH did not
bring about any further increase. Taken together, the results suggest that ATX administered i.p.
either in the presence or absence of RAC does not alter electrically evoked phasic-like DA signals
recorded in the ventral striatum.
We also failed to detect any DA transients in response to ATX or RAC with i.p.
administration, as shown in the representative recordings in Figure 2C. Only AMPH, which was
used as a positive control, and when co-administered with a second dose of RAC, elicited DA
transients. Similar results were found across all animals in Design 1a and Design 1b. While the
lack of presynaptic DA effects of ATX in the striatum was expected, the lack of ATX effects on
DA transients was not and could be due to slow drug adsorption with the i.p. route of
administration. Because drug adsorption is about twice as high for i.v. of administration
(Woodard, 1965), we investigated ATX effects with this route using Designs 2a and 2b (Figure
1B, n = 4 and 4, respectively) for the remainder of the study.
ATX does not alter electrically evoked phasic-like DA signals
Figure 3A shows representative recordings demonstrating the effects of SAL, ATX, RAC,
and AMPH on electrically evoked phasic-like DA responses measured in the ventral striatum
following i.v. administration and using Design 2a. The individual voltammograms (INSET in each
panel) and pseudo-color plot displaying all voltammograms collected during the measurement in
time (below each [DA] versus time recording) indicate that DA is the predominant analyte evoked
by MFB stimulation for pre-drug and drug conditions. ATX did not alter [DA]max or the dynamics
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of the evoked response compared to SAL. In contrast, both RAC and AMPH increased [DA]max
and its duration. AMPH appeared to further enhance the RAC-altered evoked response.
Figure 3B shows average values of [DA]max for each 5 min-epoch and expressed as a
percent change from the pre-drug condition. One-way repeated measures ANOVA revealed a
significant effect of time for Design 2a (left panel; F11,44 = 9.02, p < 0.0001) and Design 2b (right
panel; F11,33 = 4.78, p = 0.0002). To further analyze drug effects, the time series of [DA]max shown
in each 5-min epoch was compiled into drug groups in Figure 3C. Because post-hoc tests revealed
no significant differences between pre-drug and SAL groups, a single control for [DA]max was
created by combining both groups. One-way repeated measures ANOVA with pseudo-replication
revealed a significant effect of drug on [DA]max for Design 2a (left panel; F3,56 = 32.14, p <
0.0001). Post-hoc tests revealed no significant increase in [DA]max with ATX (p = 0.7786),
whereas both RAC (p = 0.0001) and AMPH (p < 0.0001) significantly increased [DA]max
compared to control and ATX. A significant effect of drug was also found for Design 2b (right
panel; F3,32 = 10.57, p < 0.0001), and post-hoc tests showed that while RAC significantly increased
[DA]max (p = 0.0055), ATX and AMPH did not bring about any further increase. Thus, consistent
with i.p. administration, i.v. ATX did not alter electrically evoked phasic-like DA signals. Taken
together, these results suggest that ATX does not act presynaptically on striatal DA terminals.
ATX activates DA transients
Figure 4A shows representative recordings demonstrating the effects of SAL, ATX, RAC,
and AMPH on DA transients in the ventral striatum following i.v. administration and using Design
2a. Each panel shows a PCR-resolved [DA] versus time recording with transients denoted by a
red asterisk. Above each recording are individual voltammograms comparing transients (or
baseline; red) to the electrically evoked signal (black). Below each recording is the pseudo-color
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plot showing all voltammograms collected during the measurement in time. Whereas no DA
transients were observed in the SAL recording, DA transients were present after ATX, RAC, and
AMPH administration. Voltammograms confirm DA as the origin of these transients.
Figure 4B shows the average number of DA transients for each 5 min-epoch. One-way
repeated measures ANOVA revealed a significant effect of time for Design 2a (left panel; F11,33 =
6.03, p < 0.0001) and Design 2b (right panel; F11,33 = 6.86, p < 0.0001). Similar to the analysis of
[DA]max above, the time series of DA transients was compiled into drug groups with a single
control in Figure 4C. One-way repeated measures ANOVA with pseudo-replication revealed a
significant effect of drug on DA transients for Design 2a (left panel; F3,9 = 22.07, p = 0.0002).
Post-hoc tests revealed a significant increase in DA transients with ATX (p = 0.0039), RAC (p =
0.0001), and AMPH (p < 0.0001) compared to control. A significant effect of drug was also found
for Design 2b (right panel; F3,9 = 18.46, p = 0.0003). Post-hoc tests revealed a significant increase
in DA transients with ATX (p < 0.0001) and AMPH (p < 0.0001) but not RAC (p = 0.1765)
compared to control and that AMPH increased DA transients compared to RAC (p = 0.0102).
Taken together, these results suggest that ATX elicits DA transients in the ventral striatum with
and without RAC.
ATX and basal DA
Figure 5A shows representative recordings demonstrating the effects of SAL, ATX, RAC,
and AMPH on the change in basal (i.e., non-electrically evoked) DA levels in the ventral striatum
following i.v. administration and using Design 2a. Each panel shows a raw FSCV (black) and
PCR-resolved (red) [DA] versus time recording. Below each recording is the pseudo-color plot
showing all voltammograms collected during the measurement in time. For the SAL trace, there
appears to be minimal changes in the FSCV record and not unexpectedly, considerable overlap
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with the PCA-resolved record. For ATX, RAC, and AMPH, there appears to be a steady decrease
in the FSCV signal after drug injection, with more pronounced effects for RAC and AMPH and
indicative of the non-DA changes in the pseudo-color plots. PCR processing produced no change
in basal DA levels with ATX, but revealed increases with RAC and AMPH.
Figure 5B shows average values of Δ[DA] for each 5 min-epoch. One-way repeated
measures ANOVA revealed a significant effect of time for Design 2a (left panel; F11,77 = 14.03, p
< 0.0001) and Design 2b (right panel; F11,33 = 22.7, p = 0.0115). Per the analysis of [DA]max and
DA transients, the time series of Δ[DA] was compiled into drug groups with a single control in
Figure 5C. One-way repeated measures ANOVA with pseudo-replication revealed a significant
effect of drug on Δ[DA] for Design 2a (left panel; F3,9 = 86.59, p < 0.0001) and Design 2b (left
panel; F3,9 = 9.03, p < 0.0044). However, post-hoc tests revealed that only AMPH caused a
significant increase in Δ[DA] with Design 2a (left panel; p < 0.0001) and Design 2b (right panel;
p = 0.0059). Taken together, these results suggest that ATX does not alter basal DA levels in the
striatum.
Discussion
The goal of the present study was to investigate the effects of the non-stimulant ADHD
drug, ATX, on striatal DA signaling measured in real time using FSCV at a CFM. ATX did not
alter electrically evoked phasic-like DA signals and basal DA levels, consistent with a lack of
presynaptic effects on DA terminals in the ventral striatum. However, and indicative of proximal
effects involving an activation of burst firing by DA neurons, ATX elicited DA transients.
Collectively, these results suggest that, in addition to well-recognized actions of elevating NE and
DA levels in the PFC, activation of phasic DA signaling in the ventral striatum is a potential
mechanism by which ATX elicits therapeutic effects for treatment of ADHD.
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ATX and electrically evoked phasic-like DA signals
Electrically evoked DA signals measured in real-time by FSCV at a CFM reflect the
opposing actions of exocytotic DA release and DA uptake (Wightman et al., 1988). The
electrically evoked DA responses evaluated in this study also mimic the amplitude and dynamics
of naturally occurring DA transients (Robinson et al., 2008). Thus, because ATX did not alter
[DA]max and the dynamics of these electrically evoked responses, we conclude that ATX does not
presynaptically alter phasic DA signaling in the ventral striatum. In contrast, the D2 DA receptor
antagonist, RAC, increased [DA]max and the duration of these electrically evoked phasic-like DA
signals. The effects of RAC are consistent with blockade of presynaptic DA autoreceptors in the
ventral striatum and the subsequent increase in DA release and decrease in DA uptake (Wu et al.,
2002). Similarly, although not further increasing [DA]max above RAC levels significantly, AMPH
also increases DA release and decreases DA uptake (Avelar et al., 2013; Covey et al., 2013;
Daberkow et al., 2013).
Our results with ATX are in alignment with the high selectivity of ATX for NET and its
low binding affinity to DAT (Bymaster et al., 2002). Anatomical studies have demonstrated that
the ventral striatum receives noradrenergic projections from the locus coeruleus (LC) (Berridge et
al., 1997), as well as from the nucleus tractus solitarius (NTS) (Delfs et al., 1998). Extracellular
DA released in the ventral striatum may be non-preferentially cleared by NET similar to the PFC
(Yamamoto & Novotney, 1998). However, the ventral striatum is predominantly innervated by
VTA DA neurons and thus, has a greater population of DAT as compared to NET. Therefore, the
relative abundance of DAT in the ventral striatum, coupled with the high selectivity of ATX for
NET, is presumably the cause for negligible ATX effects on [DA]max and the duration of
electrically evoked phasic-like DA signals recorded in the ventral striatum.
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ATX and basal DA levels
Our study with FSCV at a CFM coupled to the chemometrics approach of PCR showed no
significant ATX-induced changes in basal DA levels in the ventral striatum. This result concurs
with previous microdialysis results, which showed no increase in dialysate DA collected in the
nucleus accumbens with ATX (Bymaster et al., 2002) and other selective NET inhibitors, such as
desipramine and reboxetine (Linner et al., 2001). Similar to results with electrically evoked
phasic-like DA signals, the lack of effect of ATX on basal DA levels is inconsistent with a
presynaptic target of DA terminals in the ventral striatum. Similar to ATX, RAC showed no
significant effects on Δ[DA], while AMPH significantly increased this FSCV measure of basal
DA levels. These later results are not entirely consistent with previous microdialysis studies,
which have shown that both drugs elevate striatal dialysate DA (Hertel et al., 1999; Kuczenski et
al., 1991). The basis for this discrepancy is not entirely clear but must be related to different
analytical properties of the monitoring techniques. Microdialysis exhibits excellent chemical
resolution and sensitivity, but its large probe damages adjacent tissue confounding quantitative
studies (Borland et al., 2005; Watson et al., 2006). On the other hand, FSCV provides superior
temporal and spatial resolution but is more limited by sensitivity and selectivity and hence,
requires coupling with PCR to resolve DA from interferents (Keithley & Wightman, 2011). Recent
studies in the mouse striatum have suggested basal DA levels to be approximately 100 nM
(Atcherley et al., 2014). Because FSCV coupled to PCR has detected changes in basal DA in the
lower nanomolar ranges (~5 to 40 nM; (Hart et al., 2014), this approach appears to be suitable for
investigating the effects of ATX on basal DA levels.
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ATX activates DA transients in the ventral striatum
Here we show that ATX, a selective NET blocker, elicits DA transients in the ventral
striatum. Because ATX appears devoid of presynaptic effects on DA terminals in the ventral
striatum, this result is consistent with an upstream action involving the activation of burst firing
by DA neurons (Sombers et al., 2009). Indeed, the functional correlation between burst firing of
DA neurons and the appearance of DA transients in DA terminal fields is well established through
studies with behaving animals in response to rewards and reward-predicting cues (Schultz, 1998;
Covey et al., 2013; Clark et al., 2010; Covey et al., 2014) and also with psychostimulants, such as
cocaine and AMPH (Shi et al., 2000; Shi et al., 2004; Stuber et al., 2005; Koulchitsky et al., 2012;
Daberkow et al., 2013). Previous studies have also shown other selective NET inhibitors to induce
burst firing in VTA DA neurons (Shi et al., 2000; Linner et al., 2001; Friedman et al., 2008),
perhaps mediated indirectly by the PFC and/or directly within the VTA (Darracq et al., 1998;
Grenhoff et al., 1993; Grenhoff & Svensson, 1993). Confidence in the present ATX-induced
activation of DA transients is supported by the excellent agreement between the observed lack of
activation of DA transients by RAC alone in the anesthetized preparation but an increase after
subsequent administration of psychostimulant, i.e., AMPH, and previous studies (Venton &
Wightman, 2007; Park et al., 2010). Taken together, our results suggest that ATX, a non-stimulant,
thus shares activation of phasic DA signaling with psychostimulants such as AMPH and cocaine.
Although our study does not elucidate the precise mechanism of action by which ATX
elicits DA transients, there is evidence supporting a few possible explanations. By inhibiting NET,
ATX elevates extracellular NE levels in the PFC, which receives dense noradrenergic input from
the LC (Ferrucci et al., 2013). Increased cortical NE activates the post-synaptic α-1 adrenergic
receptors and causes excitation of PFC neurons. The subsequent post-synaptic excitatory effect of
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cortical glutamatergic afferents to the VTA can cause burst firing of DA neurons (Thierry et al.,
1979; Sesack & Pickel, 1992; Karreman & Moghaddam, 1996; Darracq et al., 1998). Supporting
this hypothesis are reports showing that stimulation of PFC neurons selectively increases burst
firing in the VTA and enhances DA release in the nucleus accumbens (Murase et al., 1993; Taber
et al., 1995), whereas application of glutamate receptor antagonist decreases extracellular DA
levels in this ventral striatal region (Taber et al., 1995). Furthermore, the VTA receives direct
noradrenergic innervation from the LC (Jones & Moore, 1977; Grenhoff et al., 1993) and other
brain stem regions (Mejias-Aponte et al., 2009). Direct application of NE depolarizes ~60% of the
DA neurons in the VTA (Grenhoff et al., 1995). Additionally, DA neuron firing increases in
response to single-pulse stimulation of the LC and is attenuated in the presence of prazosin
(Grenhoff et al., 1993; Grenhoff & Svensson, 1993). Thus, by blocking NE uptake at
noradrenergic terminals, and thereby increasing extracellular levels of NE in the NET rich PFC,
as well as in the VTA, ATX may be mediating an excitatory effect on the VTA DA neurons,
leading to their phasic activation.
Therapeutic action of ATX in ADHD
The activation of DA transients in the ventral striatum by ATX may have important
implications to its relevance as an ADHD drug within the purview of the DTD model. It is
suggested that psychostimulant drugs, like AMPH (Adderall®) and MPH (Ritalin®), used to treat
ADHD produce their therapeutic effects by increasing the amplitude of the DA transient elicited
by the predictive cue and/or the reward during reinforcement learning (Tripp & Wickens, 2008).
This enhanced transient activation would in turn improve associative learning between cue and
reward, which is hampered in ADHD patients. Thus, activation of phasic DA signaling may be an
additional contributing factor to the therapeutic effects of ATX in treatment of ADHD. However,
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an important caveat to consider is ATX dose. The dose of ATX that we used (10 mg/kg) was
selected, because it robustly elevates dialysate DA levels in the PFC but not in the dorsal striatum
and nucleus accumbens (Bymaster et al. 2002). Previous reports with other selective NET
inhibitors, nisoxetine (Shi et al., 2000; Shi et al., 2004) and reboxetine (Linner et al., 2001), have
also used i.v. administration at similar doses to demonstrate an activation of burst firing of
midbrain DA neurons. However, the dose of 10 mg/kg for ATX may not be therapeutically
relevant and hence, the precise pharmacologic implications of ATX for treating ADHD needs
further study, especially using awake animals due to the blunting effects of anesthesia on burst
firing of DA neurons (Kelland et al., 1990; Chiodo, 1988).
Conclusion
Here we show, for the first time, that ATX, a selective NET-inhibitor, elicits DA transients
in the ventral striatum. Hence, activation of phasic DA signaling may be a common property of
ADHD drugs. Eliciting DA transients, which are the extracellular phasic signals important for
reward processing and reinforcement learning, may be a possible additional mechanism of ATX
in causing its therapeutic effects in ADHD. However, this suggestion must be confirmed by further
study using therapeutic doses of ATX in freely behaving animal models.
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Figure 1. Experimental design and data analysis. A) Experimental Design 1 for i.p. drug
administration. Electrical stimulation is indicated by black arrows; drug injection is
indicated by blue arrows. Design 1a: Three pre-drug electrically evoked signals were
collected, followed by administration of ATX. After collecting a 60-min post-ATX trace,
RAC was injected. Collection of the 60-min post-RAC trace was follwed by administration
of the positive control, AMPH, co-administered with a second dose of RAC. Design 1b:
Similar to Design 1a, except that the order of administration of RAC and ATX was
reversed. B) Experimental Design 2 for i.v. drug administration. Electrical stimulation is
indicated by black arrows; drug injection is indicated by blue arrows. Design 2a: Three
pre-drug electrically evoked signals were collected, followed by administration of SAL,
which was the negative control. ATX was injected after the 10-min post-SAL trace,
followed by admistration of RAC and AMPH (positive control). Design 2b: Similar to
Design 2a, except that the order of administration of RAC and ATX was reversed. C) (Top)
FSCV (black line) and PCR (red line) traces for exemplar recordings pre- (left) and post(right) AMPH. (Bottom) Pseudo-color plots for both representative recordings showing
multiple analytes in the non-electrically evoked portion. The PCR resolved trace was used
to analyze changes in basal DA (Δ[DA]). Below is a 20-s representative recording showing
DA transients in the non-electrically evoked portion of the 5-min post-AMPH epoch. The
PCR-resolved DA trace was used to analayze DA transients. (INSET, Top) DA transients
on the PCR trace are denoted by red asterisks. (INSET, Bottom) Pseudo-color plot
confirms identity of the analyte as DA. D) An exemplar electrically evoked DA signal
determined from the raw FSCV signal was used to determine the maximal amplitude of
the electrically evoked DA signal ([DA]max).
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Figure 2. Effects of ATX, RAC, and AMPH (i.p) on electrically evoked phasic-like DA
signals. A) (Top) DA signals elicited by electrical stimulation: pre-drug, post-RAC, post
ATX, and post-AMPH (left to right). INSET. Individual voltammograms taken from the peak
signal (white vertical line on the pseudo-color plot) identify the analyte as DA. (Bottom)
Pseudo-color plots of electrically evoked DA signals collected pre-drug, post-RAC, postATX, and post-AMPH (left to right). White horizontal line on the pseudo-color plot identifies
the DA peak oxidative potential where the evoked DA trace was collected. B) average
[DA]max. One-way repeated measures ANOVA revealed a significant effect of drug on
[DA]max in Design 1a (left panel) and 1b (right panel). Data are expressed as a percent of predrug and are mean ±SEM.*, p < 0.05. C) Effects of ATX, RAC, and AMPH (i.p) on DA
transients. Representative pseudo-color plots of the non-electrically evoked portion of predrug, RAC, ATX, and AMPH recordings (left to right). INSET. Normalized voltammograms
taken from the electrically-evoked response (black line) and a DA transient or baseline (red
line) collected at the white vertical line in the pseudo-color plot.
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Figure 3. Effects of SAL, ATX, RAC, and AMPH on electrically evoked phasic-like DA signals.
A) (Top) DA signals elicited by electrical stimulation: SAL, ATX, RAC, and AMPH (left to
right). INSET. Individual voltammograms taken from the peak signal (white vertical line in the
pseudo-color plot) identify the analyte as DA. (Bottom) Pseudo-color plots of electrically
evoked DA signals SAL, ATX, RAC, and AMPH (left to right). White horizontal line in the
pseudo-color plot identifies the DA peak oxidative potential where the evoked DA trace was
collected. B) One-way repeated measures ANOVA revealed a significant effect of time on
[DA]max in Design 2a (left panel) and 2b (right panel). Data are expressed as a percent of predrug and are mean ±SEM. C) One-way repeated measures ANOVA revealed a significant
effect of drug on [DA]max in Design 2a (left panel) and 2b (right panel). Data are expressed as
a percent of pre-drug and are mean ±SEM.*, p < 0.05.
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Figure 4. Effects of SAL, ATX, RAC, and AMPH on DA transients. A) Representative
recordings of DA transients in the ventral striatum. (Top) Normalized voltammograms taken
from the electrically-evoked response (black line) and a DA transient or baseline (red line)
collected at the white vertical line in the pseudo-color plot. (Middle) DA transients (denoted
by red asterisks) are displayed in the PCR-resolved DA trace. (Bottom) A pseudo-color plot
underneath serially displays all voltammograms in time. B) One-way repeated measures
ANOVA showed a significant effect of time on the number of DA transients in Design 2a (left
panel) and 2b (right panel). Data are mean ±SEM. C) One-way repeated measures ANOVA
showed a significant effect of drug on the number of DA transients in Design 2a (left panel)
and 2b (right panel). Data are mean ±SEM.*, p < 0.05.
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Figure 5. Effects of ATX, RAC, and AMPH on changes in basal DA in the ventral striatum. A)
(Top) FSCV (black line) and PCR (red line) traces for exemplar recordings: SAL, ATX, RAC,
and AMPH (left to right). (Bottom) Pseudo-color plots for representative recordings showing
multiple analytes in the non-electrically evoked portion. The PCR resolved trace was used to
analyze changes in basal DA. B) One-way repeated measures ANOVA showed a significant
effect of time on Δ[DA] in Design 2a (left panel) and 2b (right panel). Data are mean ±SEM.
C) One-way repeated measures ANOVA showed a significant effect of drug on Δ[DA] in
Design 2a (left panel) and 2b (right panel). Data are mean ± SEM. *, p < 0.05.
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CHAPTER II
DOPAMINE TRANSPORTER-INHIBITING PSYCHOSTIMULANTS INCREASE
EXOCYTOTIC DOPAMINE RELEASE
ABSTRACT
There is increasing evidence suggesting that psychostimulants elevate brain extracellular
dopamine not only by inhibiting dopamine uptake but also by increasing exocytotic dopamine
release. Psychostimulant-induced increases in exocytotic dopamine release have been
demonstrated by fitting electrically evoked dopamine signals measured using fast-scan cyclic
voltammetry at a carbon-fiber microelectrode to the diffusion gap model, which describes
dopamine diffusing across a gap between release and uptake sites and measurement at the
microsensor. However, this model fails to describe features regularly observed in evoked
dopamine signals, such as “hang-up”, the slow return of dopamine to baseline, and incongruous
changes in “lag”, the time for dopamine to increase after stimulus initiation, and “overshoot”, the
continued dopamine increase after stimulus cessation. The recently proposed restricted diffusion
model addresses these issues by dividing extracellular space into inner and outer compartments.
Dopamine is initially released into the inner compartment and is transported by restricted diffusion
to the outer compartment, where it is measured by the microsensor and cleared by dopamine
uptake. Hang-up, attributed to dopamine adsorption to the microsensor, is removed from data prior
to analysis. Here we analyze the in vivo effects of the psychostimulants, amphetamine, cocaine,
and modafinil, on exocytotic dopamine release and dopamine uptake. Parameters describing these
mechanisms and previously determined with the diffusion gap model were compared to those
obtained by the restricted diffusion model. Both models similarly demonstrated an increase in
exocytotic dopamine release and inhibition of dopamine uptake for all three psychostimulants.
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These results support the hypothesis that psychostimulants elevate extracellular dopamine by
targeting both exocytotic dopamine release and dopamine uptake.
INTRODUCTION
The mechanism of psychostimulant action has been the subject of intense scrutiny over
the years. These drugs cause their behavioral effects, at least in part, by elevating extracellular DA
in the dorsal and ventral striatum (Carboni et al., 1989; Di Chiara & Imperato, 1988; Carboni et
al., 1989). A well-established action of one class of psychostimulants is inhibition of the dopamine
transporter (DAT), which regulates extracellular DA levels by clearing released DA. Based on
their interactions with DAT on DA terminals, psychostimulants have been classified as being
cocaine-like or amphetamine (AMPH)-like. Cocaine-like drugs are traditional inhibitors of DAT,
whereas AMPH-like drugs are DAT “substrates” (Seiden et al., 1993). AMPH-like
psychostimulants are also referred to as “releasers”, due to their property of eliciting reverse
transport by DAT thereby causing non-action potential-dependent DA efflux (Sulzer et al., 1995).
While both cocaine-like and AMPH-like drugs share the mechanism of competitive inhibition of
DA uptake, these psychostimulants have been thought to differ in their actions on vesicular pools
of DA and exocytotic DA release. Whereas cocaine has been shown to augment exocytotic DA
release (Jones et al., 1995; Venton et al., 2006), AMPH depletes vesicular DA pools and hence,
compromises exocytotic DA release (Jones et al., 1998; Schmitz et al., 2001). Therefore, DAT
inhibition and DA efflux driven by translocation of DA from vesicular to cytosolic pools have
been considered to be the predominant effects of AMPH action contributing to its elevation of
extracellular levels of striatal DA (Sulzer, 2011; Fleckenstein et al., 2007). Evidence from some
psychostimulant studies are in support of the hypothesis that in addition to blocking DA uptake,
psychostimulants also increase exocytotic DA release. These studies report increased exocytotic
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DA release with methylphenidate (MPH) and other DAT blockers, such as nomifensine (Venton
et al., 2006; Chadchankar et al., 2012; Lee et al., 2001), in addition to cocaine (Jones et al., 1995;
Venton et al., 2006). However, AMPH enhancing exocytotic DA release still remains a
controversial idea due to discrepant results obtained from in vitro (Jones et al., 1998; Schmitz et
al., 2001) and in vivo studies (Daberkow et al., 2013; Ramsson et al., 2011).
Kinetic analysis of electrically evoked DA signals measured by fast scan cyclic
voltammetry (FSCV) at a carbon fiber microelectrode (CFM) has been used to assess the action
of psychostimulants on DA release and uptake. The Wightman model, also known as the diffusion
gap (DG) model, has been typically used. The DG model describes extracellular DA concentration
as a balance between the opposing actions of DA release and uptake (Wightman et al., 1988). The
DA measurement with FSCV is also subject to the diffusional distortions, lag (i.e., the delay in
rise of the DA signal with stimulus onset) and overshoot (i.e., the continued rise of DA signal after
stimulus cessation), arising from the presence of a gap between DA release and uptake sites on
terminals and the CFM (Wightman et al., 1988; Kawagoe et al., 1992) (Fig. 1a). Using the DG
model, we have previously reported that the psychostimulants, modafinil (MOD), AMPH, and
cocaine, not only inhibit DA uptake but also increase action potential-dependent, vesicular DA
release (Ramsson et al., 2011; Daberkow et al., 2013; Covey et al., 2013; Bobak et al., 2016).
However, demonstrated insufficiencies in the DG model have challenged its appropriateness and
hence, the finding of enhanced DA release with psychostimulants. For example, the DG model
does not hold true for DA signals that show lag without overshoot or overshoot without lag
(Moquin & Michael, 2009; Walters et al., 2014). The concept of a diffusion gap also fails to
explain another feature regularly observed in DA signals, called hang-up or the prolonged
elevation of the signal and its delayed return to baseline (Walters et al., 2014).
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A new kinetic model, called the restricted diffusion (RD) model, has been recently
developed (Walters et al., 2015; Walters et al., 2014) to address limitations with the DG model.
The RD model (Fig. 1b) divides brain extracellular space into inner and outer compartments, with
DA released into the inner compartment and transported by restricted diffusion to the outer
compartment where it is detected by the CFM and cleared by uptake. The restricted diffusion of
DA from the inner to outer compartment could be due to several factors, such as pockets of
extracellular dead space, DA binding sites, and tissue tortuosity (Sykova & Nicholson, 2008). The
model convincingly explains lag as a consequence of DA being held up, or restricted, as it diffuses
to the outer compartment after release, and overshoot as the delayed arrival of DA to the CFM
after overcoming the diffusional restrictions in its path. Through this concept of delayed DA
transport from the release site to the CFM, the RD model also effectively provides plausible
scenarios for the fast and slow-type responses recorded in the rat dorsal striatum, which are not
always amenable to description by the DG model (Taylor et al., 2013; Walters et al., 2014).
Additionally, hang-up has been attributed to adsorption of DA to the CFM surface and can be
corrected using an equation expressing the hang-up component as a balance between the
concentration of DA adsorbed and desorbed (Walters et al., 2015). Hence, the RD model improves
the kinetic analysis of electrically evoked DA signals to resolve the presynaptic mechanisms of
DA release and uptake.
The purpose of this study was to compare the analysis of psychostimulant effects on
electrically evoked DA signals measured by FSCV at a CFM using the DG and RD models.
Specifically, we used the RD model to re-analyze already published electrically evoked DA
signals altered by MOD, AMPH, and cocaine and evaluated by the DG model. Our results support
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the hypothesis that the DAT-inhibiting psychostimulants, AMPH, cocaine, and MOD, also
augment action potential-dependent, exocytotic DA release.
RESULTS AND DISCUSSION
Correction of raw FSCV signals
As described in Figure 2, correction for the hang-up component was required for most
electrically evoked DA signals kinetically analyzed by the RD model. The pseudo-color plot (Fig.
2A) suggests that the raw FSCV signal (black line), representing the electrically evoked signal
(Fig. 2B) and measured at the peak oxidation potential for DA (indicated by horizontal white line
on the pseudo-color plot), originates from DA. The individual voltammogram (Fig. 2A inset),
determined at the peak of the evoked signal (indicated by the vertical white line on the pseudocolor plot), is also consistent with DA. This raw FSCV trace shows the hang-up component (i.e.
it does not return quickly to baseline), because DA uptake would lower extracellular DA faster.
To correct for hang-up, this component was first calculated using Eq. 4, which uses first-order
rate constants to describe hang-up as a balance between DA adsorption to and desorption from the
CFM surface. The calculated hang-up component (Fig. 2B; gray line) was then subtracted from
the raw response measured by FSCV (black line) to generate a corrected signal (red line). It is
noteworthy that previous uses of the DG model described herein did not involve any hang-up
correction. However, the signals that were analyzed using this model were routinely cut off in
time to avoid distortion by the hang-up component.
When present, the effect of pH on the raw FSCV signal, usually an alkaline shift due to
changes in blood flow elicited by the same electrical stimulation evoking DA release in urethaneanesthetized animals (Robinson et al., 2003; Venton et al., 2003), was removed using the
differential correction method (Venton et al., 2003). As can be seen in pseudo-color plot of Figure
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3A, electrical stimulation elicits electrochemical features other than DA, the most prominent of
which is pH. As shown in Figure 3B, the raw electrically evoked FSCV signal (black line) is
distorted by this pH signal, which is highlighted by a considerable drop below baseline. The
identity of the analytes elicited by electrical stimulation is perhaps more clearly demonstrated by
their respective individual voltammograms. For example, the initial signal elicited by electrical
stimulation is indicative of DA (Fig. 3A inset, left; voltammogram determined by the first vertical
white line). Slower changes in the record were confirmed as pH (Fig. 3A inset, right;
voltammogram determined by the second vertical white line). To correct for pH, its
voltammogram was determined a few seconds after stimulation and in the absence of any DA
release and used to calculate a pH signal (Fig. 3B; blue line). This signal, after adjusting to
correspond to the DA oxidative potential, was then subtracted from the raw FSCV to calculate a
pH-corrected DA signal (Fig. 3B; red line). This correction has also been applied previously to
evoked DA signals subject to analysis by the DG model. The pH subtracted signals can then be
corrected for hang-up (Fig 3B; gray line), as described above, before fitting to the RD model.
Another method that is used to resolve mixed pH and DA signals collected by FSCV is
principal component regression (PCR), a chemometrics approach (Heien et al., 2005). However,
pH change is not always the sole contributor to the measured signal, which may also be affected
by interferents such as background drift and other analytes in solution. Figure 4 shows the PCRresolved components of the same signal that was pH-corrected in Figure 3. The raw FSCV signal
(black line), which reflects contributions from multiple analytes, is resolved into its principal
components by PCR, to obtain DA (red line), pH (blue line), and background drift (green line).
The DA trace resolved from the PCR can be subsequently used for hang-up correction (gray line).
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Restricted diffusion model with hang-up correction produces better fits
Figure 5 compares a representative analysis of electrically evoked DA signals altered by
MOD (300 mg/kg) using the traditional kinetic approach, the DG model, and a new kinetic
approach, the RD model with hang-up correction. Recordings in the top panel of Figure 5A show
exemplar DA signals elicited by stimulation of the medial forebrain bundle (MFB) and measured
by FSCV at a CFM (left panel, pre-drug; right panel, MOD). Pseudo-color plots shown below and
the individual voltammograms (inset) collected at the time of peak signal (vertical white lines on
the pseudo-color plot) confirm the evoked signal (horizontal white line on the pseudo-color plot)
as DA. Administration of MOD, a wake-promoting psychostimulant (vide infra), caused a marked
increase in the amplitude and broadening of the electrically evoked DA signal as compared to the
pre-drug signal. As shown in Figure 5B the RD model with hang-up correction did indeed produce
fits that describe data with higher fidelity than the DG model. We subsequently quantitatively
compared the effects of MOD, cocaine, and AMPH on electrically evoked DA signals using the
DG model and RD model with hang-up correction.

MOD alters DA release and uptake in the dorsal striatum of anesthetized rats
Developed to treat narcolepsy (Bastoji & Jouvet, 1988), MOD is approved for the
treatment of sleep-related disorders, such as obstructive sleep apnea and shift-work sleep disorder.
Its therapeutic effects have also been investigated for treating the psychiatric disorders of attention
deficit hyperactivity disorder (Swanson et al., 2006) and depression, and drug abuse (Anderson et
al., 2009; Anderson et al., 2012). Although MOD acts on various neurotransmitter systems,
including orexin, serotonin, glutamate, and GABA, its action on DA has gained importance over
time. MOD has been classified as a DAT-inhibiting psychostimulant with low abuse potential
(Myrick et al., 2004; Deroche-Gamonet et al., 2002). While preventing DA uptake by inhibition
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of DAT has been considered to be its primary mode of action, recently MOD has also been shown
to activate phasic DA signaling, which is suggested to be an additional mechanism contributing
to its clinical effects (Bobak et al., 2016).
We have previously used the DG model to investigate the effects of MOD on electrically
evoked phasic DA signals (Bobak et al., 2016). The evoked signals are considered phasic-like
because of their resemblance to the naturally occurring phasic DA transients associated with
reinforcement learning and elicited by burst firing of DA neurons (Covey et al., 2014). Our study
demonstrated that MOD, in a time- and dose-dependent fashion, increased the amplitude of these
evoked DA signals and DA release and decreased DA uptake. Data showing the effects of MOD
at a dose of 300 mg/kg on DA release and uptake are replicated in Figure 6A and B (left) for the
pre-drug condition and 30 and 60 min post-drug. This data sub-set was statistically re-analyzed
using two-way repeated measures ANOVA for the present study. In excellent agreement with
Bobak et al. (2016), there was a significant drug-by-time interaction for [DA]p (F2,18 = 20.19, p <
0.0001), which is the index of DA release, and k (F2,18 = 14.73, p = 0.0002), the first-order rate
constant for DA uptake. Post hoc tests also demonstrated that MOD significantly increased [DA]p
(p < 0.0001 at 30 and 60 min) and decreased k (30 min: p = 0.016; 60 min: p = 0.0004), at both
time points after drug administration.
We analyzed the same electrically evoked DA signals with the RD model and hang-up
correction to determine the effects of MOD on DA release and uptake (Figure 6) and also used
two-way repeated measures ANOVA for statistical comparisons. A significant drug-by-time
interaction on Rp (F2,18 = 17.62, p < 0.0001), the term for DA release, and kU (F2,18 = 3.68, p =
0.0456), the term for DA uptake, was seen for the 3-parameter fit (Fig. 6A and B, middle). Similar
effects were observed on Rp (F2,18 = 16.85, p < 0.0001) and kU (F2,18 = 7.74, p = 0.0038) for the 4-
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parameter fit (Fig. 6A and B, right). The 4-parameter fit of the RD model is the 3-parameter fit
(i.e., Rp, kU, and kT, the transport rate constant between compartments) with the addition of kR, a
rate constant reflecting short-term changes in DA release (see Figure 1 and Methods for details).
Post hoc tests showed a significant MOD-induced increase in Rp compared to vehicle at 30 (p =
0.0003) and 60 min (p < 0.0001) for the 3-parameter fits (Fig. 6A, middle). Similar results were
seen for increased Rp with the 4-parameter fits at 30 (p = 0.0012) and 60 min (p < 0.0001) postMOD (Fig. 6A, right). As shown in Figure 6B (middle), 3 parameter-fits showed a significant
MOD-induced decrease in kU compared to vehicle at both time points post-drug (30 min: p =
0.0456 and 60 min: p = 0.0197). However, the 4-parameter fits for kU (Fig. 6B, right) showed a
significant difference from vehicle only at 60 min post-drug (p = 0.0043).
Overall, we did not observe any significant changes in the other two parameters, kT, the
transport rate constant between compartments, and kR, the rate constant reflecting short-term
changes in DA release (Fig. S1). Thus, our results with the RD model concur with Bobak et al.
(2016), which used the DG model, and support the notion that not only does MOD decrease DA
uptake, it also increases exocytotic DA release.
Fitting of PCR-treated data
The electrically evoked DA signals collected pre-drug and 30-min post-MOD and
described above were used to assess whether PCR processing with hang-up correction altered
analysis by the RD model (Fig. 7). These data were statistically analyzed using two-way repeated
measures ANOVA. Similar to unprocessed data, PCR-treated data showed a significant drug-bytime interaction for Rp with the 3-parameter fit (Fig. 7A, left; F1,6 = 23.25, p = 0.0029) and 4parameter fit (Fig. 7A, right; F1,6= 21.6, p = 0.0035), and for kU with the 3-parameter fit (Fig. 7B,
left; F1,6 = 22.4, p = 0.0032) and 4-parameter fit (Fig. 7B, right; F1,6 = 22.14, p = 0.0033). Post hoc
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tests showed a significant increase in Rp (3-parameter fit: p = 0.0015, 4-parameter fit: p = 0.0039,
Figure 7A, right and left, respectively). PCR-treated signals also showed a significant decrease in
kU (3-parameter fit p = 0.0062, 4-parameter fit: p =0.0062, Figure 7B, left). Taken together, these
results suggest that PCR processing of raw FSCV signals is appropriate for the analysis of DA
release and uptake parameters using the RD model.

AMPH alters DA release and uptake in the dorsal striatum of freely behaving rats
The psychostimulant AMPH is a potent DAT-inhibitor that competitively blocks DA
uptake and also causes non-exocytotic DA efflux through DAT reversal (Kuczenski and Segal,
1994; Fleckenstein at al., 2007). Historically, high-dose AMPH is thought to disrupt phasic DA
signaling, the action potential-dependent transient increases in extracellular DA levels elicited by
burst firing of DA neurons (Schultz, 2007), by depletion of vesicular stores of DA, which in turn
compromises exocytotic DA release (Hyman et al., 2006; Sulzer, 2011). However, conflicting
reports regarding AMPH action have previously been obtained from in vitro (Jones et al., 1998;
Schmitz et al., 2001) and in vivo (Kuhr et al., 1985; May et al., 1988) preparations, as well as from
microdialysis (Carboni et al., 1989; Kuczenski et al., 1991) and voltammetric studies (Wiedemann
et al., 1990). The basis for these discrepant results is difficult to fully understand, but it should be
considered that the in vivo preparation better replicates natural physiological responses and that
microdialysis suffers from the disadvantages of low temporal resolution and a large probe that
damages adjacent tissue, making it difficult to quantify DA levels. More recently, we have used
FSCV at a CFM in vivo to study AMPH effects on striatal DA signaling and demonstrated that a
high dose (10 mg/kg) robustly increased exocytotic DA release and decreased DA uptake in both
anesthetized (Ramsson et al., 2011) and freely behaving (Daberkow et al., 2013) rats.
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A sub-set of data previously collected in the dorsal striatum of freely behaving rats during
pre-drug recording and 5, 10, and 15 min post-AMPH (10 mg/kg) and analyzed with the DG model
(Daberkow et al., 2013) is replicated in Figures 8A and B (left). These data were statistically reanalyzed using two-way repeated measures ANOVA. In excellent agreement with Daberkow et
al. (2013), these results demonstrated a significant drug-by-time interaction for [DA]p (F3,24 = 108,
p < 0.0001), representing DA release (Fig. 8A left), and k (F3,24 = 18.37, p < 0.0001), representing
DA uptake (Fig. 8B, left). AMPH also increases [DA]p and decreased k at every time point (p <
0.05).
We used the 3- and 4-parameter fits of the RD model (Figs. 8A and B, middle and right,
respectively) and two-way repeated measures ANOVA to assess the same data. Statistical analyses
showed a significant drug-by-time interaction for Rp with the 3-parameter fit (Fig. 8A, middle;
F3,24 = 49.75, p < 0.0001) and 4-parameter fit (Fig. 8A, right; F3,24 = 17.2, p < 0.0001), and for kU
with the 3-parameter fit (Fig. 8B, middle; F3,24 = 24.97, p < 0.0001) and 4-parameter fit (Fig. 8B,
right; F3,24 = 7.71, p = 0.001). Post hoc tests showed that AMPH significantly increased Rp and
decreased kU at all time points after drug administration for both the 3- and 4-parameter fits (p <
0.0001). While we did not observe any significant changes in the kR for the 4-parameter fit, kT was
significantly decreased for both the 3- and 4-parameter fits (Fig. S2; also see next section). The
present analysis with the RD model is thus consistent with our previous analysis using the DG
model (Daberkow et al., 2013) and supports the conclusion that in addition to mechanisms such
as DA uptake inhibition, DAT reversal, and DA efflux, AMPH elevates extracellular DA in the
brain through exocytotic DA release.
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AMPH and cocaine alter DA release and uptake in the dorsal striatum of anesthetized rats
We have previously compared the effects of cocaine, which is not thought to deplete
vesicular DA stores, and AMPH, which historically is thought to deplete vesicular DA stores, to
better understand our paradoxical results showing AMPH enhancing exocytotic DA release in
awake rats (Daberkow et al., 2013). Overall, these studies demonstrated that both cocaine and
AMPH activated phasic dopamine signaling in the form of DA transients, increased DA release,
and decreased DA uptake in the dorsal striatum of anesthetized rats (Ramsson et al., 2011; Covey
et al., 2013). Thus, in contrast to the widely accepted view that AMPH and cocaine elicit opposite
effects on exocytotic DA release and phasic DA signaling, data from our lab showed that
augmentation of action-potential dependent, vesicular DA release was a common property of both
psychostimulants.
A sub-set of data from Covey et al. (2013) and showing the effects of AMPH (10 mg/kg)
and cocaine (40 mg/kg) on DA release and uptake in anesthetized rats as determined by the DG
model is replicated in Figures 9A and B, respectively (left). These data were statically re-analyzed
using two-way repeated measures ANOVA. Consistent with Covey et al. (2013), these results
demonstrated a significant drug-by-time interaction for [DA]p (F2,16 = 30.89, p < 0.0001),
representing DA release (Fig. 9A top left), and k (F2,16 = 234.1, p < 0.0001), representing DA
uptake (Fig. 9A and B, left). Both psychostimulants significantly increased [DA]p and decreased
k compared to saline controls (p < 0.05). 3- and 4-parameter RD fits of these same data revealed
a significant drug-by-time interaction for the 3-parameter (Fig. 9a, top middle: F2,16 = 46.3; p <
0.0001) and 4-parameter (Fig. 9B, right: F2,16 = 8.36; p = 0.0033) fit of Rp and for the 3-parameter
(Fig. 9B, middle: F2,16 = 771.53; p < 0.0001) and 4-parameter (Fig. 9B, right: F2,16 = 664.78; p =
< 0.0001) fit of kU. Both AMPH and cocaine significantly increased Rp (p = 0.0002) and decreased
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kU (p < 0.001) compared to saline in the 3-parameter data fits. Similarly, statistical analysis of the
4-parameter fits showed that Rp was significantly increased by AMPH (p = 0.0117) and cocaine
(p = 0.0302), and kU was significantly decreased by AMPH (p = 0.0025) and cocaine (p = 0.0205).
Overall, we also did not observe any significant changes in the other two parameters, kT and kR
(Fig. S3). The lack of significant effects of AMPH on kT for either the 3- or 4-parameter fits in
these data collected in anesthetized rats is at odds with significant decreases in kT for data collected
in awake rats (Fig. S3). While the origin of this difference is not known, it is interesting to
speculate the movement in the awake rat may have created an additional diffusion path that was
expressed as a decrease in kT. Taken together, our results with the RD model thus further support
the hypothesis that both cocaine and AMPH act similarly to increase exocytotic DA release and
inhibit DA uptake.
METHODS
Data
Data for analyses are from our previously published studies. MOD data (anesthetized rats)
were from Bobak et al. (2016; 300 mg/kg, n = 6; vehicle, n = 5). AMPH data (freely behaving
rats) were from Daberkow et al. (2013; AMPH = 10 mg/kg, n = 6; saline, n = 6). AMPH and
cocaine data (anesthetized rats) were from Covey et al. (2013; AMPH = 10 mg/kg, n= 7; cocaine
= 40 mg/kg, n = 5; saline, n = 7). With the exception of the study conducted by Daberkow et al.
(2013), which investigated effects in the dorsal striatum, Bobak et al. (2016) and Covey et al
(2013) examined dorsal as well as the ventral striatum. However, for the purpose of this
investigation, we restricted our analyses to data obtained from the dorsal striatum only.
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Animals
For all the three studies mentioned, adult Sprague-Dawley rats (250-300g) were used.
Animals were purchased from Harlan (Indianapolis, IN, USA), and housed in a light-, and
temperature-controlled vivarium. Access to food and water was provided ad libitum. All
procedures were in accordance with the National Institutes of Health Guide for the Care and Use
of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of
Illinois State University.
Surgery
For the anesthetized studies, adult male Sprague-Dawley rats were anesthetized with
urethane (1.6 g/kg) and mounted in a stereotaxic apparatus. An incision of the scalp was made,
and skin and fascia removed. Holes were drilled into the skull to implant recording electrodes, one
stimulating electrode, and one reference electrode. Using stereotaxic coordinates relative to
bregma (Paxinos & Watson, 1986), the stimulating electrode was placed in the MFB (-4.6 AP,
+1.4 ML, -7.0 DV), a CFM was placed in the dorsal striatum (+1.2 AP, +3.0 ML, -4.5 DV), and
the Ag/AgCl reference electrode was placed in the contralateral cortex. The stimulating electrode
and CFM were lowered and optimized to produce a robust electrically evoked DA signal. The
position of the electrodes was fixed for the duration of the experiment after optimization. For the
freely behaving studies, rats were anesthetized with ketamine (80 mg/kg) and xylazine (60 mg/kg)
injected i.p. before mounting in a stereotaxic frame. Reference and stimulating electrodes and a
hub to house a micromanipulator were implanted and secured to the skull. During recording in
awake rats, a fresh CFM was lowered after attaching the micromanipulator and optimized prior to
the beginning of the experiment. For both studies, the CFMs were prepared by aspirating a single
carbon fiber (r = 3.5 μm) into a borosilicate capillary tube and pulling to a taper. A chloridized
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silver wire was used as reference electrode. Twisted bipolar stimulating electrodes, with tips
spaced ~1 mm apart, were used. Stimulus pulses were optically isolated and delivered at a constant
current as 60-Hz, 24-pulse trains at a current intensity of ±300 µA.
FSCV
Electrically evoked dopamine levels were recorded using FSCV at a CFM. A triangular
waveform (-0.4 to 1.3 V and back, 400 V/s) was applied every 100 ms. An EI400 bipotentiostat
(Ensman Instruments, Bloomington, IN, USA), which was computer controlled using TarHeel-1
software (ESA, Chelmsford, MA, USA), was used to perform FSCV. The CFM was calibrated in
TRIS buffer after each experiment to convert the peak oxidation current for DA in each scan to a
concentration (Wightman et al., 2007).
Data Analysis
Electrically evoked DA signals were analyzed to determine parameters for exocytotic DA
release and DA uptake using two kinetic models:
1.

Diffusion gap model (Fig. 1A). This model postulates that brain extracellular DA

is governed by the balance between dopamine released and that which is taken back up. To be
measured, DA must diffuse across a gap between the CFM and releasing DA terminals. The
mathematical equation describing this is as follows (Wightman et al., 1988; Wu et al., 2001):
= DA

−

DA

(1)

where, [DA]p is the concentration of DA released per stimulus pulse, f is the frequency of
stimulation, and k is the first-order rate constant for DA uptake. Curve fitting of data to Eq. 1 used
non-linear regression with a simplex minimization algorithm. (Wu et al., 2001). Calculated curves
were convoluted with an impulse response function for thin layer diffusion prior to data
comparison (Kawagoe et al., 1992).
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Restricted diffusion model (Fig. 1B). This model divides the brain extracellular

2.

space into an inner and an outer compartment, and postulates that DA released into the inner
compartment diffuses in a restricted manner into the outer compartment, from where it can be
measured by the CFM and is subject to reuptake. The model comprises two equations (Walters et
al., 2015):
dDA
=
d
d DA
d

e

=

DA

− DA

(2)

− DA

(3)

where DAic is the amount (in moles) of DA in the inner compartment, Rp is the moles of DA
released per stimulus pulse, f is the stimulus frequency, kR is a first-order rate constant that signifies
modification of DA release by either short-term depression or facilitation, kT is a first order rate
constant for DA transport from inner to outer compartment, Voc is the volume of the outer
compartment (fixed at 16 µm3) (Walters et al., 2014; Walters et al., 2015; Moss & Bolam, 2008),
and kU is the first-order rate constant for DA uptake.
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Hang up correction
Before analyses using the RD model, the effect of hang-up was removed from electrically
evoked DA signals by using a correction as explained in detail by Walters et al. (2015). Briefly,
the algorithm calculates a hang-up component in terms of first-order rate constants describing the
balance between DA adsorption to and desorption from the CFM surface. The equation that
describes this balance is as follows:
d
=
d

!"

−

## Γ

(4)

where kon and koff are first-order rate constants for DA adsorption and desorption, respectively, and
C is the concentration of DA in solution in close contact with the electrode, which is the same as
the concentration detected by FSCV (Walters et al., 2015). The calculated hang-up component is
then subtracted from the measured evoked response, to give a corrected signal.
A brute-force algorithm was used for curve fitting as described in Walters et al. (2015) and
Walters et al. (2014). Curve fitting was used to set the values of the adjustable parameters in the
hang-up (Eq. 4) and DA kinetic (Eqs. 2 and 3) models. The parameters producing the best fit to
data were those that were defined by high Pearson correlation coefficients and the smallest values
of the sum of squares of the residuals.
pH correction
The effect of basic pH shifts following electrical stimulation, caused by changes in local
blood flow, was removed by using the voltammogram of the pH change occurring a few seconds
(~5 s) after stimulation and free of DA. Current for pH (measured typically at ≈-0.2 mV) was then
adjusted for the DA oxidative potential (≈+0.6 mV typically) before subtracting the pH current
from the total current measured at the DA oxidative potential.

50

PCR
For PCR, different number of stimulation pulses (12, 24, 48, 60, and 72 pulses), which
produce different electrically evoked DA concentrations, were used to construct in vivo training
sets. From these recordings, five background-subtracted voltammograms for each analyte, DA,
pH, and background drift, were collected, and the principal components, which account for most
of the relevant data, were calculated using principal component analysis (PCA). Subsequently,
each principal component was translated into the corresponding analyte units using least square
regression. Experimental recordings containing unknown sample concentrations were then
projected on to the principal components, in order to determine their amplitudes (Hermans et al.,
2008; Keithley et al., 2009).
Statistics
When appropriate, data are presented as the mean ± SEM. All statistical analyses were
performed using SAS. For the MOD (anesthetized rats) and AMPH (freely-behaving rats) studies,
a repeated-measures two-way ANOVA with drug and time as independent variables and time as
the repeated measure was used for each parameter. Post hoc comparisons were performed by a
Sidak test. Effects of AMPH and cocaine (anesthetized rats) were statistically analyzed using a
one-way ANOVA with a Dunnett’s post hoc test. Significance was set at p < 0.05.
Drugs and Chemicals
Urethane, cocaine hydrochloride, and D-amphetamine was purchased from Sigma (St.
Louis, MO, USA). MOD was provided by Research Triangle Institute-National Institute on
Drug Abuse, Raleigh, NC. All drugs were administered i.p.
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CONCLUSION
The ability to inhibit DA uptake has largely been accepted as the unifying mechanism by
which DAT-targeting psychostimulants enhance extracellular brain DA levels and cause many of
their behavioral effects (Sulzer, 2011; Fleckenstein et al., 2007). As compared to other
psychostimulants in this class, AMPH has been shown to elicit greater extracellular DA
concentrations, due to its unique action of reversing the direction of DA transport via DAT and
causing DA efflux. While most of the cocaine-like psychostimulants are also known to activate
action potential-dependent DA signaling, AMPH has been excluded from causing this effect;
instead, AMPH disrupts this type of DA signaling by depleting vesicular DA stores and decreasing
exocytotic DA release (Sulzer, 2011; Hyman, 2005). Indeed, non-action potential-dependent DA
efflux, driven by the depletion of readily releasable DA stores, has been proposed to be the
hallmark of AMPH action in the brain.
Kinetic modeling of electrically evoked DA signals in vivo, measured before and after drug
administration by FSCV at a CFM, provides valuable information about the effects of DATtargeting psychostimulant on the presynaptic mechanisms of DA release and uptake (Wightman
et al., 1988; Wu et al., 2001). The DG model of kinetic analysis, which attributes the diffusional
distortions of lag and overshoot to a gap between DA releasing terminals and the CFM, has been
used to quantitatively resolve the release and uptake components of evoked DA signals. With the
DG model, previous results obtained by our lab are at odds with the accepted model of AMPH
action. Indeed, these studies have failed to demonstrate compromised phasic DA signaling due to
disrupted exocytotic DA release with high-dose AMPH and instead have shown increased phasic
DA signaling and augmented exocytotic DA release, more consistent with the actions of cocaine
and cocaine-like DAT inhibitors (Ramsson et al., 2011; Daberkow et al., 2013; Covey et al., 2013).
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Moreover, we have more recently shown that an atypical psychostimulant, MOD, also increases
DA release (Bobak et al., 2016). However, drawbacks of the DG model, such as its insufficiency
in describing the discordant appearance of lag and overshoot, and the presence of hang-up in DA
signals, have rendered its application for DA kinetic analysis debatable, thereby raising questions
on the finding of psychostimulants augmenting exocytotic DA release. On the other hand, the RD
model, based on the concept of restricted diffusion of released DA and its delayed detection at the
CFM, more faithfully describes DA signals in terms of lag, overshoot, and hang-up (Walters et
al., 2014; Walters 2015).
This study therefore sought to compare results for the psychostimulants, MOD, AMPH,
and cocaine, calculated using the DG model with those obtained using the RD model, with a
particular focus on assessing the previously identified psychostimulant-induced increase in DA
release. Despite their theoretical differences, both models showed amplified exocytotic DA
release and decreased DA uptake for all the psychostimulants tested, the latter in keeping with
their well-recognized role as DAT-inhibitors. We speculate that the reasons for the excellent
agreement between models is that firstly, all signals fit to the DG model were pre-selected via
optimization and placement of CFMs close to the DA releasing terminals, which presumably
downplayed the effect of the diffusion gap distorting measured DA signals. Secondly, while the
DG model was not coupled to the hang-up correction, this distortion was minimized by fitting the
early portions of the signals and avoiding the latter portions reflecting the greatest hang-up
component.
The major conclusion resulting from this study is that the DAT-targeting
psychostimulants, AMPH, cocaine, and MOD, elevate extracellular DA concentration not solely
by DA uptake inhibition, but also by upregulating action potential-dependent DA release. This
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result is of particular significance with regards to AMPH action, which has historically been
considered to elevate extracellular DA levels in the brain primarily by vesicular DA depletion
driving DA efflux. We thus propose that DAT inhibitors are misnamed, because this group of
psychostimulants may also enhance DA release. Cellular mechanisms of how these
psychostimulants increase exocytotic DA release have been investigated. Cocaine has been shown
to mediate its effects of enhancing DA release by mobilizing synapsin-bound DA vesicles, which
are part of the long-term storage pool (Venton et al., 2006). MPH causes upregulated DA release
via α-synuclein, a protein involved in vesicular trafficking (Chadchankar et al., 2012). That
AMPH may act also exert its effects on synaptic proteins is a speculation worth testing. Previously
results from our lab have demonstrated that AMPH also augments exocytotic DA release by
increasing DA synthesis and inhibiting DA degradation, presumably leading to increased cytosolic
DA and vesicular loading (Avelar et al., 2013).
Augmentation of vesicular DA release is especially important for activation of the DA
transients of phasic DA signaling, which play a critical role in reinforcement learning, goaldirected behavior, and drug addiction (Stuber et al., 2005). Evidence from AMPH and MOD
studies shows that enhanced DA release tracks increases in [DA]max, the maximal amplitude of
electrically evoked phasic-like DA signals, better than reduced DA uptake (Bobak et al., 2016;
Covey, et al., 2013; Daberkow, et al., 2013). Assuming that electrically evoked phasic-like DA
signals mimic naturally occurring DA transients, a higher correlation of [DA]max with exocytotic
DA release compared to DA uptake indicates that increased exocytotic DA release may be
responsible for the increased amplitude of DA transients with psychostimulants (Stuber et al.,
2005; Daberkow et al., 2013). The augmentation of exocytotic DA release causing the increased
amplitude of DA transients may therefore be an important action mediating the abuse potential of
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addictive drugs. Hence, this study contributes towards establishment a new unifying mechanism
of action of psychostimulants in activating phasic DA signaling through increased exocytotic DA
release, in addition to inhibition of DA uptake. This study also highlights the need to reconsider
and re-assess mechanisms of action of psychostimulants. While most such drugs are potentially
abusive, many are also used as medication. For example, MOD is a commonly prescribed wakepromoting agent (Wise et al., 2007), and AMPH and MPH are used in the treatment of attention
deficit hyperactivity disorder (Swanson et al., 1995). Therefore, it is imperative that a detailed
understanding of ways in which these drugs act should be explored and elaborated further, in order
to aid in better drug development and to improve efforts towards controlling drug abuse.

55

REFERENCES

1. Anderson, A. L., Li, S. H., Biswas, K., McSherry, F., Holmes, T., Iturriaga, E. et al. (2012).
Modafinil for the treatment of methamphetamine dependence. Drug and alcohol dependence,
120, 135-141.
2. Anderson, A. L., Reid, M. S., Li, S. H., Holmes, T., Shemanski, L., Slee, A. et al. (2009).
Modafinil for the treatment of cocaine dependence. Drug and alcohol dependence, 104, 133-139.
3. Avelar, A. J., Juliano, S. A., & Garris, P. A. (2013). Amphetamine augments vesicular dopamine
release in the dorsal and ventral striatum through different mechanisms. Journal of
neurochemistry, 125, 373-385.
4. Bastoji, H. & Jouvet, M. (1988). Successful treatment of idiopathic hypersomnia and narcolepsy
with modafinil. Progress in neuro-psychopharmacology and biological psychiatry, 12, 695-700.
5. Bobak, M. J., Weber, M. W., Doellman, M. A., Schuweiler, D. R., Athens, J. M., Juliano, S. A.
et al. (2016). Modafinil activates phasic dopamine signaling in dorsal and ventral striata. Journal
of Pharmacology and Experimental Therapeutics, 359, 460-470.
6. Carboni, E., Imperato, A., Perezzani, L., & Di Chiara, G. (1989). Amphetamine, cocaine,
phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in
the nucleus accumbens of freely moving rats. Neuroscience, 28, 653-661.
7. Chadchankar, H., Ihalainen, J., Tanila, H., & Yavich, L. (2012). Methylphenidate modifies
overflow and presynaptic compartmentalization of dopamine via an alpha-synuclein-dependent
mechanism. Journal of Pharmacology and Experimental Therapeutics, 341, 484-492.
8. Covey, D. P., Juliano, S. A., & Garris, P. A. (2013). Amphetamine Elicits Opposing Actions on
Readily Releasable and Reserve Pools for Dopamine. Plos One, 8.

56

9. Covey, D. P., Roitman, M. F., & Garris, P. A. (2014). Illicit dopamine transients: reconciling
actions of abused drugs. Trends in neurosciences, 37, 200-210.
10. Daberkow, D. P., Brown, H. D., Bunner, K. D., Kraniotis, S. A., Doellman, M. A., Ragozzino,
M. E. et al. (2013). Amphetamine Paradoxically Augments Exocytotic Dopamine Release and
Phasic Dopamine Signals. Journal of Neuroscience, 33, 452-463.
11. Deroche-Gamonet, V., Darnaudery, M., Bruins-Slot, L., Piat, F., Le Moal, M., & Piazza, P.
(2002). Study of the addictive potential of modafinil in naive and cocaine-experienced rats.
Psychopharmacology, 161, 387-395.
12. Di Chiara, G. & Imperato, A. (1988). Drugs abused by humans preferentially increase synaptic
dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the
National Academy of Sciences of the United States of America, 85, 5274-5278.
13. Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., & Hanson, G. R. (2007). New insights
into the mechanism of action of amphetamines. Annu.Rev.Pharmacol.Toxicol., 47, 681-698.
14. Heien, M. L. A. V., Khan, A. S., Ariansen, J. L., Cheer, J. F., Phillips, P. E. M., Wassum, K. M.
et al. (2005). Real-time measurement of dopamine fluctuations after cocaine in the brain of
behaving rats. Proceedings of the National Academy of Sciences of the United States of America,
102, 10023-10028.
15. Hermans, A., Keithley, R. B., Kita, J. M., Sombers, L. A., & Wightman, R. M. (2008).
Dopamine Detection with Fast-Scan Cyclic Voltammetry Used with Analog Background
Subtraction. Analytical Chemistry, 80, 4040-4048.
16. Hyman, S. E. (2005). Addiction: A Disease of Learning and Memory. American Journal of
Psychiatry, 162, 1414-1422.

57

17. Hyman, S. E., Malenka, R. C., & Nestler, E. J. (2006). Neural mechanisms of addiction: the role
of reward-related learning and memory. Annu.Rev.Neurosci., 29, 565-598.
18. Jones, S. R., Gainetdinov, R. R., Wightman, R. M., & Caron, M. G. (1998). Mechanisms of
amphetamine action revealed in mice lacking the dopamine transporter. The Journal of
Neuroscience, 18, 1979-1986.
19. Jones, S. R., Garris, P. A., & Wightman, R. M. (1995). Different effects of cocaine and
nomifensine on dopamine uptake in the caudate-putamen and nucleus accumbens. Journal of
Pharmacology and Experimental Therapeutics, 274, 396-403.
20. Kawagoe, K. T., Garris, P. A., Wiedemann, D. J., & Wightman, R. M. (1992). Regulation of
transient dopamine concentration gradients in the microenvironment surrounding nerve terminals
in the rat striatum. Neuroscience, 51, 55-64.
21. Keithley, R. B., Heien, M. L., & Wightman, R. M. (2009). Multivariate concentration
determination using principal component regression with residual analysis. Trends in analytical
chemistry : TRAC, 28, 1127-1136.
22. Kuczenski, R., Segal, D. S., & Aizenstein, M. L. (1991). Amphetamine, cocaine, and
fencamfamine: relationship between locomotor and stereotypy response profiles and caudate and
accumbens dopamine dynamics. The Journal of neuroscience, 11, 2703-2712.
23. Kuhr, W. G., Ewing, A. G., Near, J. A., & Wightman, R. M. (1985). Amphetamine attenuates the
stimulated release of dopamine in vivo. Journal of Pharmacology and Experimental
Therapeutics, 232, 388-394.
24. Lee, T. H., Balu, R., Davidson, C., & Ellinwood, E. H. (2001). Differential time-course profiles
of dopamine release and uptake changes induced by three dopamine uptake inhibitors. Synapse,
41, 301-310.

58

25. May, L. J., Kuhr, W. G., & Wightman, R. M. (1988). Differentiation of Dopamine Overflow and
Uptake Processes in the Extracellular Fluid of the Rat Caudate Nucleus with FastGÇÉScan In
Vivo Voltammetry. Journal of neurochemistry, 51, 1060-1069.
26. Moquin, K. F. & Michael, A. C. (2009). Tonic autoinhibition contributes to the heterogeneity of
evoked dopamine release in the rat striatum. Journal of neurochemistry, 110, 1491-1501.
27. Moss, J. & Bolam, J. P. (2008). A dopaminergic axon lattice in the striatum and its relationship
with cortical and thalamic terminals. The Journal of Neuroscience, 28, 11221-11230.
28. Myrick, H., Malcolm, R., Taylor, B., & LaRowe, S. (2004). Modafinil: preclinical, clinical, and
post-marketing surveillanceGÇöa review of abuse liability issues. Annals of Clinical Psychiatry,
16, 101-109.
29. Paxinos, G. & Watson, C. (1986). The rat brain in stereotaxic coordinates. (second ed.) New
York: Academic Press.
30. Ramsson, E. S., Howard, C. D., Covey, D. P., & Garris, P. A. (2011). High Doses of
Amphetamine Augment, Rather Than Disrupt, Exocytotic Dopamine Release in the Dorsal and
Ventral Striatum of the Anesthetized Rat. Journal of neurochemistry, 119, 1162-1172.
31. Robinson, D. L., Venton, B. J., Heien, M. L. A. V., & Wightman, R. M. (2003). Detecting
subsecond dopamine release with fast-scan cyclic voltammetry in vivo. Clinical Chemistry, 49,
1763-1773.
32. Schmitz, Y., Lee, C. J., Schmauss, C., Gonon, F., & Sulzer, D. (2001). Amphetamine distorts
stimulation-dependent dopamine overflow: effects on D2 autoreceptors, transporters, and
synaptic vesicle stores. The Journal of Neuroscience, 21, 5916-5924.
33. Schultz, W. (2007). Behavioral dopamine signals. Trends in neurosciences, 30, 203-210.

59

34. Seiden, L. S., Sabol, K. E., & Ricaurte, G. A. (1993). Amphetamine: effects on catecholamine
systems and behavior. Annual Review of Pharmacology and Toxicology, 33, 639-676.
35. Stuber, G. D., Wightman, R. M., & Carelli, R. M. (2005). Extinction of cocaine selfadministration reveals functionally and temporally distinct dopaminergic signals in the nucleus
accumbens. Neuron, 46, 661-669.
36. Sulzer, D. (2011). How Addictive Drugs Disrupt Presynaptic Dopamine Neurotransmission.
Neuron, 69, 628-649.
37. Sulzer, D., Chen, T. K., Lau, Y. Y., Kristensen, H., Rayport, S., & Ewing, A. (1995).
Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse
transport. The Journal of Neuroscience, 15, 4102-4108.
38. Swanson, J. M., Greenhill, L. L., Lopez, F. A., Sedillo, A., Earl, C. Q., Jiang, J. G. et al. (2006).
Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity
disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by
abrupt discontinuation. J.Clin.Psychiatry, 67, 137-147.
39. Swanson, J. M., McBurnett, K., Christian, D. L., & Wigal, T. (1995). Stimulant medications and
the treatment of children with ADHD. In Advances in clinical child psychology (pp. 265-322).
Springer.
40. Sykova & Nicholson, C. (2008). Diffusion in Brain Extracellular Space. Physiological Reviews,
88, 1277.
41. Taylor, I. M., Ilitchev, A. I., & Michael, A. C. (2013). Restricted Diffusion of Dopamine in the
Rat Dorsal Striatum. ACS Chemical Neuroscience, 4, 870-878.

60

42. Venton, B. J., Michael, D. J., & Wightman, R. M. (2003). Correlation of local changes in
extracellular oxygen and pH that accompany dopaminergic terminal activity in the rat
caudateGÇôputamen. Journal of neurochemistry, 84, 373-381.
43. Venton, B. J., Seipel, A. T., Phillips, P. E. M., Wetsel, W. C., Gitler, D., Greengard, P. et al.
(2006). Cocaine Increases Dopamine Release by Mobilization of a Synapsin-Dependent Reserve
Pool. The Journal of Neuroscience, 26, 3206-3209.
44. Walters, S. H., Robbins, E. M., & Michael, A. C. (2015). Modeling the Kinetic Diversity of
Dopamine in the Dorsal Striatum. ACS Chemical Neuroscience, 6, 1468-1475.
45. Walters, S. H., Taylor, I. M., Shu, Z., & Michael, A. C. (2014). A Novel Restricted Diffusion
Model of Evoked Dopamine. ACS Chemical Neuroscience, 5, 776-783.
46. Wiedemann, D. J., Basse-Tomusk, A., Wilson, R. L., Rebec, G. V., & Wightman, R. M. (1990).
Interference by DOPAC and ascorbate during attempts to measure drug-induced changes in
neostriatal dopamine with Nafion-coated, carbon-fiber electrodes. Journal of neuroscience
methods, 35, 9-18.
47. Wightman, R. M., Amatorh, C., Engstrom, R. C., Hale, P. D., Kristensen, E. W., Kuhr, W. G. et
al. (1988). Real-time characterization of dopamine overflow and uptake in the rat striatum.
Neuroscience, 25, 513-523.
48. Wightman, R. M., Heien, M. L., Wassum, K. M., Sombers, L. A., Aragona, B. J., Khan, A. S. et
al. (2007). Dopamine release is heterogeneous within microenvironments of the rat nucleus
accumbens. Eur.J.Neurosci., 26, 2046-2054.
49. Wise, M. S., Arand, D. L., Auger, R. R., Brooks, S. N., Watson, N. F., & American Academy of
Sleep Medicine (2007). Treatment of narcolepsy and other hypersomnias of central origin. Sleep,
30, 1712-1727.

61

50. Wu, Q., Reith, M. E., Wightman, R. M., Kawagoe, K. T., & Garris, P. A. (2001). Determination
of release and uptake parameters from electrically evoked dopamine dynamics measured by realtime voltammetry. Journal of neuroscience methods, 112, 119-133.

62

CHAPTER II FIGURES

Figure 1. Schematic representation of DG and RD models. In the DG model (left panel),
released vesicular DA (orange) ([DA]p; f is frequency of stimulation) diffuses through a gap
(l), before it reaches the detecting CFM and is cleared by DAT through first-order DA uptake
(k). According to Eq. 1, this model describes extracellular DA levels as a balance between DA
release and uptake. The RD model (right panel) divides the extracellular space into inner
compartment (IC) and outer compartment (OC) and postulates that released DA (Rp; kR is a
first-order rate constant signifying short-term changes in DA release) is transported from IC to
OC where DA is measured by the CFM and DA uptake take place. The restricted diffusion of
DA and DA uptake are described by the first-order rate constants, kT and kU, respectively. The
RD model is comprised of two equations (Eqs. 2 and 3), each defining DA levels in the IC and
OC, respectively.
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Figure 2. Hang-up correction of electrically evoked DA signals. A) Pseudo-color plot of an
exemplar electrically evoked DA signal. (Inset) Individual voltammogram (see vertical while
line I pseudo-color plot). B) DA concentration obtained from the raw FSCV trace (see
horizontal white line in the pseudo-color plot) is displayed in black. The hang-up component
(gray) was calculated and subtracted from the raw signal to produce a hang-up corrected DA
trace (red).
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Figure 3. pH correction of electrically evoked DA signals. A) Pseudo-color plot of an exemplar
electrically evoked DA signal showing basic pH changes (blue portion). (Inset) Individual
voltammograms identify the analytes as DA (red), at the time point represented by the left
vertical white line, and pH (blue), at the time point indicated by the right vertical white line of
the pseudo-color plot. B) Concentration vs. time plots of the DA trace obtained from raw the
FSCV recording (black line; see upper horizontal white line on the pseudo-color plot) and after
pH correction (red). The blue line represents the pH current measured at the peak pH potential
(see lower horizontal white line on the pseudo-color plot). Hang-up subtracted trace (gray) was
obtained by performing hang-up correction on the pH corrected signal.
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Figure 4. Hang-up correction of PCR-resolved DA signals. Concentration vs. time plots of the
PCR-resolved DA trace (red) obtained from raw the FSCV recording (black). PCR also
resolved the raw signal into principal components for pH (blue) and background drift (green).
Hang-up subtracted trace (gray) was obtained by performing hang-up correction on the PCRresolved DA trace.
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Figure 5. Comparison of fits obtained by DG and RD models. A) (Top) DA signals elicited by
electrical stimulation before (left) and 60 min after (right) MOD (300 mg/kg) administration.
(Inset) Individual voltammograms taken from the peak signal (white vertical line on pseudocolor plots) identifies the analyte as DA. (Bottom) 15-s pseudo-color plots for the pre- and
post-MOD evoked signals. White horizontal line identifies the DA peak oxidative potential
where the evoked DA trace was collected. B) Fits produced for each of these exemplar signals
using the DG (red line) and RD (blue line) models. The DG model was fit to FSCV data (red
dots), and the RD model was applied on FSCV data that were hang-up corrected (blue dots).
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Figure 6. MOD activates exocytotic DA release and reduces DA uptake. A) An increase in the
DA release parameter from the DG model (left), and the 3-parameter (middle), and 4-parameter
(right) fits of the RD model was seen in response to administration of MOD (300 mg/kg). B)
MOD causes a decrease in DA uptake as shown by the reduced uptake parameter of the DG
(left), and the 3-parameter (middle) and 4-parameter (right) fits of the RD model. Data are
expressed as a percent of pre-drug and are the mean ± SEM. Data were analyzed for
significance using two-way repeated measures ANOVA (p < 0.05).
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Figure 7. MOD increases DA release and reduces DA uptake in PCR-treated DA traces. A) 3parameter (left) and 4-parameter (right) fits of the RD model showed that MOD increases Rp
at 30 min post-drug. B) 3-parameter (left) and 4-parameter (right) fits of the RD model showed
that MOD significantly reduces kU at 30 min post-drug. Data are expressed as a percent of predrug and are the mean ± SEM. Data were analyzed for significance using two-way repeated
measures ANOVA (p < 0.05).
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Figure 8. AMPH activates exocytotic DA release and reduces DA uptake. A) An increase in
the DA release parameter from the DG model (left), and the 3-parameter (middle) and 4parameter (right) fits of the RD model was seen in response to administration of AMPH (10
mg/kg). B) AMPH caused a decrease in DA uptake as shown in the reduced uptake parameter
of the DG model (left), and the 3-parameter (middle) and 4-parameter (right) fits of the RD
models. Data are expressed as a percent of pre-drug and are the mean ± SEM. Data were
analyzed for significance using two-way repeated measures ANOVA (p < 0.05).
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Figure 9. Comparison of effects of AMPH and cocaine on DA release and uptake. A) Both
AMPH and cocaine significantly increased exocytotic DA release as shown by the increased
release parameter of the DG model (left), and 3-parameter (middle) and 4-parameter (right) fits
of the RD model. B) AMPH and cocaine reduced DA uptake as shown by the decreased uptake
parameter of the DG model (left) and 3-parameter (middle) and 4-parameter (right) fits of the
RD model. Data are expressed as a percent of pre-drug and are the mean ± SEM. Data were
analyzed for significance using one-way ANOVA (p < 0.05).
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CHAPTER II SUPPLEMENTARY FIGURES
S1. Two-way repeated measures ANOVA of DA signals altered by MOD (300 mg/kg) and
collected in anesthetized rats showed no significant effects of drug, time, and drug-by-time
interaction on the parameters kT from the 3- and 4-parameter fits, and kR from the 4-parameter fits.
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S2. Two-way repeated measures ANOVA of DA signals altered by AMPH (10 mg/kg) and
collected in awake rats showed significant effects of drug (F1,32 = 73.05; p < 0.0001), time (F3,32
= 27.06; p < 0.0001), and drug-by-time interaction (F3,32 = 20.00; p < 0.0001) on the parameter
kT for the 3-parameter fits. AMPH was significantly different from vehicle at all time points after
drug administration (p < 0.0001). 4-parameter fits also showed significant effect of drug (F1,31 =
95.7; p < 0.0001), time (F3,31 = 40.01; p < 0.0001), and drug-by-time interaction (F3,31 = 44.65; p
< 0.0001). kR from the 4-parameter fits did not change significantly.
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S3. Two-way repeated measures ANOVA of DA signals altered by AMPH (10 mg/kg) and
cocaine (40 mg/kg) and collected in anesthetized rats showed no significant effects of drug, time,
and drug-by-time interaction on the parameters kT from the 3- and 4-parameter fits, and kR from
the 4-parameter fits in dorsal striatum of anesthetized rats.
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